Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Yaa-Hui DongChia-Hsuin ChangJou-Wei LinWei-Shun YangLi-Chiu WuSengwee TohPublished in: Diabetes, obesity & metabolism (2022)
Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors appeared to have comparable effectiveness with regard to several cardiovascular outcomes overall, but their comparative effectiveness may vary in certain patient subgroups.